Rockwell Medical names Raymond Pratt CMO
This article was originally published in Scrip
Dr Raymond Pratt has joined Rockwell Medical, a biopharmaceutical company targeting end-stage renal disease and chronic kidney disease with innovative products, as chief medical officer. Dr Pratt previously worked at Shire Pharmaceutical Development from 2003-2010, most recently as vice-president of R&D and the scientific leader in the emerging business unit and renal business unit.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.